Veysi Kavalcı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Veysi Kavalcı has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abdulmecit Afşin
Clinic of Cardiology, Malatya Turgut Ozal University Faculty of Medicine, Malatya, Turkey
1 shared publication - Ayşe Hoşoğlu
Department of Cardiology, Baskent University Hospital Ankara Türkiye
1 shared publication - Cemil Can
Adıyaman University Faculty of Medicine, Adıyaman Training and Research Hospital, Adıyaman, Türkiye
1 shared publication - Deniz Merde Özdemir
Department of Endocrinology and Metabolism Adiyaman University Education and Research Hospital Adiyaman Turkey
1 shared publication - Erkan Markirt
Department of Endocrinology and Metabolism Adiyaman University Education and Research Hospital Adiyaman Turkey
1 shared publication - Hakan Kaya
ADIYAMAN ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication
Latest Publications
- 27 January 2026
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- No. 1
The relationship between lactate to albumin ratio and in-hospital mortality in critically ill patients with acute decompensated heart failure
Aim: This study aimed to evaluate the association between admission lactate to albumin ratio (LAR) and in-hospital mortality in critically ill patients hospitalized with acute decompensated heart failure (ADHF).Material sand Methods: This retrospective single-center study included 87 adult patients admitted to a coronary intensive care unit (ICU) with ADHF. LAR was calculated using admission laboratory values. Patients were classified according to in-hospital survival status. Clinical, laboratory, and echocardiographic variables were analyzed to identify predictors of in-hospital mortality. Receiver operating characteristic (ROC) analysis was performed to assess the prognostic performance of the LAR.Results: In-hospital mortality occurred in 29 of 87 patients (33.3%). Median lactate levels were significantly higher in non-survivors compared with survivors (3.47 vs. 2.10 mmol/L, p < 0.001). The LAR was also higher in non-survivors (0.93 vs. 0.59, p = 0.002), while left ventricular ejection fraction (LVEF) was lower (28.2% vs. 36.1%, p = 0.006). In multivariable logistic regression analysis, mechanical ventilation (adjusted OR 80.8, p < 0.001) and LVEF (adjusted OR 0.92 per %, p = 0.016) were independently associated with in-hospital mortality, whereas the LAR was not (p = 0.266). ROC analysis demonstrated fair discrimination for the LAR in predicting mortality (AUC 0.706).Conclusion: Although higher LAR values were associated with mortality in unadjusted analysis, this marker did not provide independent prognostic value beyond established indicators of disease severity in critically ill patients with ADHF.
- 27 January 2026
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- No. 1
The relationship between lactate to albumin ratio and in-hospital mortality in critically ill patients with acute decompensated heart failure
Aim: This study aimed to evaluate the association between admission lactate to albumin ratio (LAR) and in-hospital mortality in critically ill patients hospitalized with acute decompensated heart failure (ADHF).Material sand Methods: This retrospective single-center study included 87 adult patients admitted to a coronary intensive care unit (ICU) with ADHF. LAR was calculated using admission laboratory values. Patients were classified according to in-hospital survival status. Clinical, laboratory, and echocardiographic variables were analyzed to identify predictors of in-hospital mortality. Receiver operating characteristic (ROC) analysis was performed to assess the prognostic performance of the LAR.Results: In-hospital mortality occurred in 29 of 87 patients (33.3%). Median lactate levels were significantly higher in non-survivors compared with survivors (3.47 vs. 2.10 mmol/L, p < 0.001). The LAR was also higher in non-survivors (0.93 vs. 0.59, p = 0.002), while left ventricular ejection fraction (LVEF) was lower (28.2% vs. 36.1%, p = 0.006). In multivariable logistic regression analysis, mechanical ventilation (adjusted OR 80.8, p < 0.001) and LVEF (adjusted OR 0.92 per %, p = 0.016) were independently associated with in-hospital mortality, whereas the LAR was not (p = 0.266). ROC analysis demonstrated fair discrimination for the LAR in predicting mortality (AUC 0.706).Conclusion: Although higher LAR values were associated with mortality in unadjusted analysis, this marker did not provide independent prognostic value beyond established indicators of disease severity in critically ill patients with ADHF.
- Open Access
- 21 November 2025
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 35 (3) , 294
Recurrent Takotsubo: Interpreting the 5.9-Fold 30-Day Cardiovascular Mortality Signal
- 21 November 2025
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 35 (3) , 294
Open AccessRecurrent Takotsubo: Interpreting the 5.9-Fold 30-Day Cardiovascular Mortality Signal
- 3 September 2025
- Published by SAGE Publications in Angiology
- Vol. 77 (7) , 926
Letter: Beyond the TC/HDL-C Ratio: A Nuanced View on Predicting Carotid Plaque in Ischemic Stroke
- 3 September 2025
- Published by SAGE Publications in Angiology
- Vol. 77 (7) , 926
Letter: Beyond the TC/HDL-C Ratio: A Nuanced View on Predicting Carotid Plaque in Ischemic Stroke
- Open Access
- 5 August 2025
- Published by Springer Nature in The Cardiothoracic Surgeon
- Vol. 33 (1) , 1-2
Clarifying methodological nuances in Hassan et al.’s assessment of STS score performance in Pakistan
- 5 August 2025
- Published by Springer Nature in The Cardiothoracic Surgeon
- Vol. 33 (1) , 1-2
Open AccessClarifying methodological nuances in Hassan et al.’s assessment of STS score performance in Pakistan
- Open Access
- 4 August 2025
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 30 (5) , e70101
Effect of Dapagliflozin Treatment on Index of Cardiac Electrophysiological Balance in Patients With Heart Failure With Reduced Ejection Fraction
Background: Dapagliflozin (DAPA), a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, may attenuate the risk of ventricular arrhythmia (VA) through its antiarrhythmic properties in patients with heart failure with reduced ejection fraction (HFrEF). The antiarrhythmic mechanisms of SGLT2 inhibitors are not fully known. Recently, the index of cardiac electrophysiological balance (ICEB) has been posited as a robust indicator for predicting VA risk. ICEB reflects the balance between ventricular depolarization and repolarization. This study was conducted to investigate the effects of DAPA treatment on ICEB in a cohort of patients with HFrEF.Methods: A total of 235 HFrEF patients undergoing DAPA treatment were enrolled in the study. Each participant underwent a comprehensive 12‐lead electrocardiography (ECG) assessment prior to treatment initiation and approximately 6 months posttreatment. ICEB values were compared before and after treatment.Results: The analysis revealed a statistically significant reduction in the QT interval (427.51 ± 13.87 vs. 347.75 ± 11.21 ms, p < 0.001), corrected QT interval (QTc) (458.34 ± 29.71 vs. 393.37 ± 13.21 ms, p < 0.001), T peak‐to‐end (Tp‐e) interval (85.41 ± 3.52 vs. 71.18 ± 3.16 ms, p < 0.001), Tp‐e/QTc ratio (0.186 ± 0.009 vs. 0.180 ± 0.003, p < 0.001), ICEB (4.59 ± 0.65 vs. 3.77 ± 0.15, p < 0.001), following approximately 6 months of DAPA treatment.Conclusion: In addition to ventricular repolarization distribution indices, the regression of the ICEB values after DAPA treatment in patients with HFrEF shows that DAPA treatment improves the balance between ventricular depolarization and repolarization and reduces the risk of VA in these patients.
- 4 August 2025
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 30 (5) , e70101
Open AccessEffect of Dapagliflozin Treatment on Index of Cardiac Electrophysiological Balance in Patients With Heart Failure With Reduced Ejection Fraction
Background: Dapagliflozin (DAPA), a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, may attenuate the risk of ventricular arrhythmia (VA) through its antiarrhythmic properties in patients with heart failure with reduced ejection fraction (HFrEF). The antiarrhythmic mechanisms of SGLT2 inhibitors are not fully known. Recently, the index of cardiac electrophysiological balance (ICEB) has been posited as a robust indicator for predicting VA risk. ICEB reflects the balance between ventricular depolarization and repolarization. This study was conducted to investigate the effects of DAPA treatment on ICEB in a cohort of patients with HFrEF.Methods: A total of 235 HFrEF patients undergoing DAPA treatment were enrolled in the study. Each participant underwent a comprehensive 12‐lead electrocardiography (ECG) assessment prior to treatment initiation and approximately 6 months posttreatment. ICEB values were compared before and after treatment.Results: The analysis revealed a statistically significant reduction in the QT interval (427.51 ± 13.87 vs. 347.75 ± 11.21 ms, p < 0.001), corrected QT interval (QTc) (458.34 ± 29.71 vs. 393.37 ± 13.21 ms, p < 0.001), T peak‐to‐end (Tp‐e) interval (85.41 ± 3.52 vs. 71.18 ± 3.16 ms, p < 0.001), Tp‐e/QTc ratio (0.186 ± 0.009 vs. 0.180 ± 0.003, p < 0.001), ICEB (4.59 ± 0.65 vs. 3.77 ± 0.15, p < 0.001), following approximately 6 months of DAPA treatment.Conclusion: In addition to ventricular repolarization distribution indices, the regression of the ICEB values after DAPA treatment in patients with HFrEF shows that DAPA treatment improves the balance between ventricular depolarization and repolarization and reduces the risk of VA in these patients.